NCT01049360已完成2 期
Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 128
- 试验地点
- 20
- 主要终点
- Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID) in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD) beginning with a 2-week run-in period and with a 7-10 day washout each between treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand the study procedures and be willing to participate in the study as indicated by signing the ICF and HIPAA form
- •Be male or female aged 40 to 80 years, inclusive
- •Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)
- •Be a current or former cigarette smoker with a smoking history of at least 10 pack-years
- •Have post-albuterol/salbutamol FEV1 values ≥ 30% and < 80% of the predicted value. FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after inhalation of albuterol/salbutamol.
- •Have post-albuterol/salbutamol FEV1/FVC values < 70% (ie, 100 × post- albuterol/salbutamol FEV1/FVC < 70%).
- •If female, be at least 1 year postmenopausal or surgically sterile (defined as having a hysterectomy or tubal ligation). Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening
- •Be in good stable health (as judged by the Investigator) other than the COPD, based on medical history, physical examination, ECG, spirometry, and clinical laboratory data evaluations
- •Have COPD symptoms and FEV1 values at the time of randomization that are stable compared with those at Screening (Visit 1), according to the Investigator's medical judgment
排除标准
- •Have been hospitalized for an acute COPD exacerbation within 3 months before screening
- •Have any respiratory tract infection (including the upper respiratory tract) or signs of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit 1).
- •Have any clinically significant respiratory conditions other than COPD
- •Have a history or presence of asthma verified from medical records
- •Have used theophylline (including long-acting theophylline) within the previous 3 months before study entry
- •Have Stage II hypertension, defined as systolic pressure of 160 and above, and diastolic pressure of 100 and above
- •Chronic use of oxygen therapy ≥ 15 hours a day
- •Have a history, current diagnosis, or presence of exercise-induced bronchospasm
- •Have a body mass index ≥ 40 kg/m2
- •Have participated in an pulmonary rehabilitation program within the previous 3 months
- •Have clinically significant cardiovascular conditions
- •Have uncontrolled infection resulting from human immunodeficiency virus and/or active hepatitis
- •Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.
- •Have narrow-angle glaucoma
- •Have a history of hypersensitivity reaction (including report of paradoxical bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2 adrenergic agonists, or any other inhaled medication or any component thereof
- •Have a QTcB, as indicated in the centralized reading report, above 470 msec in the resting ECGs performed at Screening (Visit 1) and/or patients who are using medications that may prolong the QT interval
- •Have clinically relevant abnormalities in the results of clinical laboratory tests, in ECG parameters other than QTc, in results of the physical examination,
- •Have any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
- •Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history of sleep apnea syndrome or any disease related with sleep disturbances such as restless legs syndrome or somnambulism)
研究组 & 干预措施
Aclidinium 400 μg / Formoterol 12 μg
Experimental
Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
干预措施: Aclidinium 400 μg / Formoterol 12 μg (Drug)
Aclidinium 400 μg / formoterol 6 μg
Experimental
Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
干预措施: Aclidinium 400 μg / Formoterol 6 μg (Drug)
Aclidinium 400 μg
Experimental
Aclidinium bromide 400 μg administered twice-daily (BID)
干预措施: Aclidinium 400 μg (Drug)
Formoterol 12 μg
Active Comparator
Formoterol fumarate 12 μg twice-daily
干预措施: Formoterol 12 μg (Drug)
Placebo
Placebo Comparator
Placebo twice-daily
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)
时间窗: 0 to 12 hours post-dose on Day 14
次要结局
- Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)(Day 14)
- Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)(Day 14)
研究者
研究点 (20)
Loading locations...
相似试验
终止
4 期
Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe PsoriasisPsoriasisNCT02829424Assistance Publique Hopitaux De Marseille78
已完成
3 期
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.Essential HypertensionNCT05288400Servier150
已完成
3 期
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose RegimensModerate to Severe Plaque-type PsoriasisNCT01406938Novartis Pharmaceuticals967
已完成
3 期
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)Diabetes Mellitus, Type 2NCT00728351Novartis Pharmaceuticals317
已完成
3 期
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirHIV InfectionNCT00708162Gilead Sciences724